25 completed, 11 recruiting, 6 terminated, 4 active not recruiting. 22 Not applicable, 14 Phase 2, 4 Phase 1, 2 Phase 4, 1 Early Phase 1.
Follow Ductal Carcinoma in Situ: new trials by email Literature Review of Ductal Carcinoma in Situ trials Research Report on Ductal Carcinoma in Situ
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS) Magtrace - Ductal Carcinoma in Situ | Phase 2 | Suspended | University of Florida | 30 | 2026-10-01 | 2026-09-11 |
| CAN1012 in Pre-Malignant DCIS and LCIS CAN1012 - Ductal Carcinoma in Situ, Lobular Carcinoma in Situ | Phase 1 | Recruiting | Providence Health & Services | 24 | 2026-09-16 | 2026-09-24 |
| HISMAR: Intraoperative Margin Assessment Using the Histolog® Scanner to Reduce Reoperation in Breast-Conserving Surgery Histolog® Scanner - Breast Cancer, Ductal Carcinoma In Situ | Not applicable | Not yet recruiting | Hôpital du Valais | 228 | 2026-09-01 | 2026-04-14 |
| Breast Tumour Size Measurement by Field Cycling Imaging Field-Cycling Imaging research scan, 3T MRI research scan - Breast Cancer, Ductal Carcinoma In Situ | Not yet recruiting | University of Aberdeen | 12 | 2026-04-01 | 2026-03-25 | |
| Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions Novel cavity marking technique - Ductal Carcinoma in Situ, Breast Cancer | Not applicable | Recruiting | University of Florida | 50 | 2025-10-27 | 2026-09-09 |
| A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients. Magic Ink - Ductal Carcinoma in Situ, Stage I Breast Cancer | Not applicable | Recruiting | Barbara Ann Karmanos Cancer Institute | 30 | 2025-08-18 | 2025-09-18 |
| Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST) Breast Radiotherapy - Breast Cancer, Early-stage Breast Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 90 | 2025-02-19 | 2026-09-03 |
| Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion Tamoxifen 10 mg Tablet, Intermittent caloric restriction, Step counter Device - BRCA Mutation, PALB2 Gene Mutation | Phase 2 | Completed | European Institute of Oncology | 110 | 2024-06-21 | 2026-09-11 |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment Tamoxifen, Exemestane, Letrozole - Ductal Carcinoma in Situ | Phase 2 | Recruiting | QuantumLeap Healthcare Collaborative | 400 | 2024-02-17 | 2026-09-28 |
| Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor - Ductal Carcinoma in Situ | Phase 1 | Recruiting | Finn, Olivera, PhD | 50 | 2024-02-07 | 2026-10-16 |
| Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer Preoperative PBI - Breast Cancer, Ductal Carcinoma in Situ | Phase 2 | Recruiting | Yonsei University | 47 | 2023-10-13 | 2024-11-07 |
| Demographics, Characteristics and Outcomes of Male Breast Cancer Patients at Methodist Health System managing Male Breast Cancer Patients at Methodist Health System - Ductal Carcinoma in Situ, Invasive Lobular Breast Carcinoma | Completed | Methodist Health System | 8 | 2023-05-04 | 2026-03-27 | |
| Excisional Vacuum-Assisted Breast Biopsy Vacuum-assisted excisional biopsy, Not excisional biopsy - Atypical Ductal Hyperplasia, Ductal Carcinoma in Situ | Not applicable | Unknown | European Institute of Oncology | 300 | 2023-01-17 | 2023-07-21 |
| EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients Survey Assessments, Diet Recall, Blood Biomarker Collection - Breast Cancer, Ductal Carcinoma In Situ | Recruiting | Thomas Jefferson University | 200 | 2022-12-21 | 2026-03-17 | |
| Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) stereotactic body radiation therapy - Ductal Carcinoma in Situ, Invasive Ductal Carcinoma of Female Breast | Recruiting | RPCR, Inc. | 200 | 2022-08-15 | 2022-08-05 | |
| An Efficacy Study of the Xoft® Axxent® eBx® IORT System® "Lite" Intra-operative Radiation Therapy - IORT - Invasive Ductal Carcinoma, Ductal Carcinoma In Situ | Not applicable | Withdrawn | Xoft, Inc. | 2022-06-30 | 2022-08-02 | |
| Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ Cryoablation - Ductal Carcinoma in Situ | Not applicable | Recruiting | Glendale Adventist Medical Center d/b/a Adventist Health Glendale | 30 | 2021-11-01 | 2023-03-03 |
| Acceptability of Active Monitoring (AM) as a Treatment Option for Ductal Carcinoma in Situ (DCIS) Decision Support Tool with Active Monitoring, Decision Support Tool without Active Monitoring - Ductal Carcinoma in Situ | Not applicable | Completed | Duke University | 322 | 2021-10-12 | 2023-01-30 |
| Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ Tamoxifen 20 mg, Anastrozole 1Mg Tab - Ductal Carcinoma in Situ, Extensive Disease | Phase 2 | Recruiting | Institut Cancerologie de l'Ouest | 262 | 2021-02-03 | 2022-04-22 |
| Subzero and Scorpion Trial cryoablation - Ductal Carcinoma in Situ | Not applicable | Withdrawn | Larkin Community Hospital | 2020-11-16 | 2023-10-16 |
Showing 20 of 55. Sign in to see all of them.
Carcinoma, Intraductal, Noninfiltrating (55) · Breast Neoplasms (30) · Breast Carcinoma In Situ (4) · Carcinoma, Lobular (4) · Pain, Postoperative (2) · Carcinoma (1) · Carcinoma, Ductal (1) · Carcinoma, Ductal, Breast (1) · Hot Flashes (1) · Hyperplasia (1) · Hypersensitivity (1) · Lymphedema (1) · Margins of Excision (1) · Motor Activity (1) · Precancerous Conditions (1)
Adenocarcinoma (55) · Carcinoma in Situ (55) · Neoplasms (55) · Neoplasms by Histologic Type (55) · Neoplasms, Ductal, Lobular, and Medullary (55) · Neoplasms, Glandular and Epithelial (55) · Carcinoma (54) · Breast Carcinoma In Situ (51) · Breast Diseases (35) · Neoplasms by Site (35) · Skin Diseases (35) · Skin and Connective Tissue Diseases (35) · Pathological Conditions, Signs and Symptoms (6) · Breast Neoplasms (5) · Signs and Symptoms (4)
Tamoxifen (4) · Anastrozole (3) · Letrozole (3) · Blood Specimen Collection (2) · Cryosurgery (2) · Sentinel Lymph Node Biopsy (2) · exemestane (2) · 4-hydroxy-N-desmethyltamoxifen (1) · Acceptance and Commitment Therapy (1) · Aromatase Inhibitors (1) · Biopsy (1) · CD2-associated protein (1) · Carboplatin (1) · Chloroquine (1) · Diet (1)
Xoft, Inc. (3) · European Institute of Oncology (2) · University of Florida (2) · Yale University (2) · Alliance Foundation Trials, LLC. (1) · Atossa Therapeutics, Inc. (1) · Barbara Ann Karmanos Cancer Institute (1) · Columbia University (1) · Dana-Farber Cancer Institute (1) · Dartmouth-Hitchcock Medical Center (1) · Duke University (1) · Finn, Olivera, PhD (1) · Gangnam Severance Hospital (1) · Glendale Adventist Medical Center d/b/a Adventist Health Glendale (1) · Hôpital du Valais (1)
United States (40) · France (2) · Italy (2) · South Korea (2) · United Kingdom (2) · Australia (1) · Canada (1) · Denmark (1) · Hong Kong (1) · Portugal (1) · Switzerland (1)
Lisa Spiguel, MD (2) · A. M. Nisar Syed, MD (1) · A.M. Nisar Syed, MD (1) · Adam Currey, MD, PhD (1) · Ahkeel Allen, MD (1) · Alastair Thompson, MD (1) · Ann Partridge, MD, MPH (1) · Bernardo Bonanni, MD (1) · Bethany G Sleckman, MD (1) · Colin Simonson, MD (1) · Danny Vesprini, MD MSc FRCPC (1) · David L Kleinberg, MD (1) · Deborah Farr, M.D. (1) · Dr. Susan Love, MD (1)
PMID 19031925, PMID 20562526, PMID 27633639, PMID 30420171, PMID 30862637, PMID 33789551, PMID 35616948, PMID 36444764, PMID 39226292, PMID 39289750, PMID 39380737, PMID 39665585, PMID 39665588
2023 (1), R00CA207872 (1), R01CA150226 (1)